# Sodium Lowering and Urinary Protein Reduction Trial

Study · id `cardio:ct-nct02945969` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02945969](<https://clinicaltrials.gov/study/NCT02945969>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02945969

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.

## Technical summary

Registry record NCT02945969. Randomized; no masking; primary purpose prevention. Start 2016-11 (registry gives no type); primary completion 2021-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 151 participants (enrolled count; ClinicalTrials.gov record NCT02945969, source copy `cardio:ctgov-nct02945969-2022-12-21`, retrieved 2026-10-26)
- Start date: 2016-11 (registry gives no type) (ClinicalTrials.gov record NCT02945969, source copy `cardio:ctgov-nct02945969-2022-12-21`, retrieved 2026-10-26)
- Primary completion: 2021-01 (actual) (ClinicalTrials.gov record NCT02945969, source copy `cardio:ctgov-nct02945969-2022-12-21`, retrieved 2026-10-26)
- Completion: 2021-01 (actual) (ClinicalTrials.gov record NCT02945969, source copy `cardio:ctgov-nct02945969-2022-12-21`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02945969, source copy `cardio:ctgov-nct02945969-2022-12-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02945969-2022-12-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sodium Lowering and Urinary Protein Reduction Trial
- Acronym: SUPER
- Condition: Chronic Kidney Disease
- Condition: Albuminuria
- Intervention (Behavioral): Low Sodium Diet
- Lead sponsor: Tulane University School of Public Health and Tropical Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 5d75ca29f23381a16776436e994542098979158e70f965183962eb43a09e6e80
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
